Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Axsome Therapeutics (AXSM) Research & Development (2022 - 2025)

Axsome Therapeutics (AXSM) has disclosed Research & Development for 4 consecutive years, with $2.6 million as the latest value for Q4 2025.

  • Quarterly Research & Development fell 95.27% to $2.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $137.1 million through Dec 2025, down 26.72% year-over-year, with the annual reading at $183.3 million for FY2025, 2.03% down from the prior year.
  • Research & Development hit $2.6 million in Q4 2025 for Axsome Therapeutics, down from $40.2 million in the prior quarter.
  • In the past five years, Research & Development ranged from a high of $55.0 million in Q4 2024 to a low of $2.6 million in Q4 2025.
  • Historically, Research & Development has averaged $30.0 million across 4 years, with a median of $29.8 million in 2023.
  • Biggest five-year swings in Research & Development: soared 142.23% in 2024 and later plummeted 95.27% in 2025.
  • Year by year, Research & Development stood at $14.7 million in 2022, then soared by 109.64% to $30.8 million in 2023, then soared by 78.57% to $55.0 million in 2024, then tumbled by 95.27% to $2.6 million in 2025.
  • Business Quant data shows Research & Development for AXSM at $2.6 million in Q4 2025, $40.2 million in Q3 2025, and $49.5 million in Q2 2025.